Literature DB >> 20414763

[Urosepsis and treatment].

F M E Wagenlehner1, C Lichtenstern, M A Weigand, W Weidner.   

Abstract

Urosepsis is one of the most frequent sepsis entities. Mortality from urosepsis is nowadays mostly lower than from other entities. Sepsis syndrome is pathophysiologically characterized by a generalized infection and immune dysregulation. Exogenous microbiological and active or passive endogenous factors released from body cells initiate and accompany the immune dysregulation. Diagnosis and therapy of urosepsis need to be instigated as early as possible (within the first hour), in order to prevent cell and tissue damage in the early phase. For this reason a series of measures is started, aimed at achieving early control of the focus of infection, providing antibiotic treatment, and stabilizing respiratory and cardiovascular function in order to optimize tissue oxygenation. A significant clinical problem ensues due to increasing antibiotic resistance mainly of enterobacteria. The choice of antibiotic therefore is made on the basis of local antibiotic resistance statistics. Dosage is determined on an individual basis, as well as according to current pharmacokinetic/pharmacodynamic knowledge. The intensive care of the septic patient needs to be started as early as on patient admission and, where necessary, continued on the intensive care ward.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414763     DOI: 10.1007/s00120-010-2253-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  38 in total

Review 1.  Therapeutic challenges of urosepsis.

Authors:  F M E Wagenlehner; A Pilatz; K G Naber; W Weidner
Journal:  Eur J Clin Invest       Date:  2008-10       Impact factor: 4.686

2.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

3.  In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates.

Authors:  Ahmet Kizirgil; Kutbettin Demirdag; Mehmet Ozden; Yasemin Bulut; Yusuf Yakupogullari; Zulal Asci Toraman
Journal:  Microbiol Res       Date:  2005       Impact factor: 5.415

4.  [Epidemiology of septicaemia pathogens].

Authors:  E J K Rosenthal
Journal:  Dtsch Med Wochenschr       Date:  2002-11-15       Impact factor: 0.628

5.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.

Authors:  M H Kollef; S Ward
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

6.  Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection.

Authors:  G Elhanan; M Sarhat; R Raz
Journal:  J Infect       Date:  1997-11       Impact factor: 6.072

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

Review 8.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

Review 9.  [AGE-RAGE: a hypothesis or a mechanism?].

Authors:  Berend Isermann; Angelika Bierhaus; Per M Humpert; Gottfried Rudofsky; Triantafyllos Chavakis; Robert Ritzel; Thoralf Wendt; Michael Morcos; Christian Kasperk; Andreas Hamann; Peter P Nawroth
Journal:  Herz       Date:  2004-08       Impact factor: 1.443

10.  The Surviving Sepsis Campaign sepsis change bundles and clinical practice.

Authors:  R Phillip Dellinger; Jean-Louis Vincent
Journal:  Crit Care       Date:  2005-11-25       Impact factor: 9.097

View more
  4 in total

Review 1.  Urosepsis--Etiology, Diagnosis, and Treatment.

Authors:  Nici Markus Dreger; Stephan Degener; Parviz Ahmad-Nejad; Gabriele Wöbker; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2015-12-04       Impact factor: 5.594

2.  [Urosepsis].

Authors:  Mathias W Pletz; Sebastian Weis; Christina Forstner; Florian Wagenlehner
Journal:  Urologe A       Date:  2018-01       Impact factor: 0.639

3.  [Urosepsis].

Authors:  Mathias W Pletz; Sebastian Weis; Christina Forstner; Florian Wagenlehner
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-03       Impact factor: 0.840

4.  Prognostic Value of Adrenomedullin and Natriuretic Peptides in Uroseptic Patients Induced by Ureteroscopy.

Authors:  Wei Hu; Pang-Hu Zhou; Wei Wang; Lijun Zhang; Xiao-Bin Zhang
Journal:  Mediators Inflamm       Date:  2016-01-05       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.